388113-93-7

Basic information

• Product Name: Carbamic acid, (3-methyl-2-oxobutyl)-, 1,1-dimethylethyl ester (9CI)
• Synonyms: Carbamic acid, (3-methyl-2-oxobutyl)-, 1,1-dimethylethyl ester (9CI);CarbaMic acid, (3-Methyl-2-oxobutyl)-, 1,1-diMethylethyl ester;(3-Methyl-2-oxo-butyl)-carbamic acid tert-butyl ester
• CAS NO: 388113-93-7
• Molecular Formula: C10H19NO3
• Molecular Weight: 201.26276
• Product Categories: N-BOC
• Mol File: 388113-93-7.mol

Chemical Properties

• Appearance: /
• CAS DataBase Reference: Carbamic acid, (3-methyl-2-oxobutyl)-, 1,1-dimethylethyl ester (9CI)(CAS DataBase Reference)
• NIST Chemistry Reference: Carbamic acid, (3-methyl-2-oxobutyl)-, 1,1-dimethylethyl ester (9CI)(388113-93-7)
• EPA Substance Registry System: Carbamic acid, (3-methyl-2-oxobutyl)-, 1,1-dimethylethyl ester (9CI)(388113-93-7)

Safety Data

• Hazardous Substances Data: 388113-93-7(Hazardous Substances Data)

Upstream product

• 24424-99-5 di-tert-butyl dicarbonate 
• 32968-46-0 ethyl 5-isopropyl-1,3-oxazole-4-carboxylate 
• 21419-25-0 1-amino-3-methyl-2-butanone monohydrochloride 
• 1068-55-9 isopropylmagnesium chloride 
• 121505-93-9 tert-butyl N-{[methoxy(methyl)carbamoyl]methyl}carbamate 

Downstream Products

• 185426-14-6 (±)-tert-butyl (2-hydroxy-3-methylbutyl)carbamate 

Relevant articles and documents

HEPATITIS B CAPSID ASSEMBLY MODULATORS

Described herein are hepatitis B capsid assembly modulators and pharmaceutical compositions comprising said compounds. The subject compounds and compositions are useful for the treatment of hepatitis B.

SUBSTITUTED HYDANTOINAMIDES AS ADAMTS7 ANTAGONISTS

The application relates to substituted hydantoinamides of formula (I) as ADAMTS7 antagonists, to processes for their preparation, their use alone or in combination for the treatment or prophylaxis of diseases, in particular of cardiovascular diseases, including atherosclerosis, coronary artery disease (CAD), peripheral vascular disease (PAD), arterial occlusive disease or restenosis after angioplasty. R1 is hydrogen, alkyl, cycloalkyl, heterocycloalkyl, heteroaryl or phenyl; R2 is hydrogen, cyano, halogen, alkylsulfonyl, alkyl, cycloalkyl or alkoxy; R3, R4, R5, R6, R7 and R8 are independently hydrogen, halogen, alkyl or alkoxy; most groups being optionally substituted; with the proviso that at least one of R2, R3, R4 is H; X1, X2, X3, X4, X5 and X6 are independently N or C; with the proviso that in each ring maximal one X is N.

SUBSTITUTED HYDANTOINAMIDES AS ADAMTS7 ANTAGONISTS

The application relates to substituted hydantoinamides of formula (I) as ADAMTS7 antagonists, to processes for their preparation, their use alone or in combination for the treatment or prophylaxis of diseases, in particular of cardiovascular diseases, including atherosclerosis, coronary artery disease (CAD), peripheral vascular disease (PAD), arterial occlusive disease or restenosis after angioplasty. R1 is hydrogen, alkyl, cycloalkyl, heterocycloalkyl, 5- to 6-membered heteroaryl or phenyl; R2 is hydrogen or alkyl; A is 5-membered heteroaryl; Z is 6- to 10-membered aryl or 5- to 10-membered heteroaryl; all groups being optionally substituted.

Long-range diastereoselectivity in an Ugi reaction: Stereocontrolled and diversity-oriented synthesis of tetrahydrobenzoxazepines

Salicylaldehydes and protected 1,2-amino alcohols have been convergently converted into a series of 2,3-dihydrobenzo[f][1,4]oxazepines, which undergo an Ugi-Joullie multicomponent reaction with unusual long-range diastereoselectivity. This protocol allows

Pyrrole derivatives

Disclosed are novel pyrrole derivatives, a process for their manufacture, pharmaceutical compositions containing such compounds and the use of such compounds in the treatment of HIV mediated diseases.